We scan new podcasts and send you the top 5 insights daily.
Dr. Patel says telisotuzumab has better efficacy and less toxicity than docetaxel in MET-high second-line NSCLC. He says giving a similar cytotoxic first can blunt the ADC, so he prefers chemoimmunotherapy first and then the MET-directed ADC at progression rather than docetaxel first for those patients.
To combat payload-related resistance, clinicians are reluctant to use two ADCs with the same payload (e.g., a deruxtecan) consecutively. The preferred strategy is to 'sandwich' a different class of chemotherapy between the two ADCs, hoping to restore sensitivity to the payload.
Real-world data suggests that using one antibody-drug conjugate (ADC) immediately after another is often ineffective. A potential strategy to overcome this resistance is to administer a different class of chemotherapy before starting the second ADC.
For high-risk, PTEN-deficient metastatic prostate cancer, a proposed strategy to maximize benefit while minimizing toxicity is sequential intensification. Clinicians can administer a triplet of ADT, an ARPI, and docetaxel first, and only after the chemotherapy course is complete, add the AKT inhibitor capivasertib to avoid severe, overlapping toxicities.
With multiple ADCs available, an emerging sequencing strategy is to alternate between different mechanisms of action, such as following a microtubule toxin-based ADC with a topoisomerase-1 inhibitor payload. This approach aims to avoid compounding specific toxicities, like neuropathy, and potentially circumvent resistance, though it is a strategy born from logic rather than clinical trial data.
Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.
When sequencing antibody-drug conjugates (ADCs), the critical factor for efficacy may not be switching the antibody target, but rather switching the cytotoxic payload. For example, using an ADC with a different payload (like tizotumab vedotin’s MMAE) after one with a topoisomerase inhibitor (like TDXD) could overcome resistance, shifting the paradigm from 'ADC after ADC' to 'payload after payload'.
Retrospective data shows that using one Antibody-Drug Conjugate (ADC) after another, particularly those with the same class of payload like TOP1 inhibitors, results in a low response rate of 10-20%. This creates a significant unmet need and a major clinical challenge for patients who progress on a first-line ADC.
In the evolving landscape of antibody-drug conjugates (ADCs), the critical factor for sequencing is likely the cytotoxic payload, not just the target antigen. A patient could respond to an ADC with a different payload after progressing on another, even if both target the same protein.
The ongoing Phase III trial for Sigvotatug Vedotin compares it against docetaxel, the current standard for second-line NSCLC. Docetaxel is known for modest efficacy and significant side effects, creating a major opportunity for the new drug to demonstrate superiority and rapidly become the new clinical standard.
Data from a head-to-head trial comparing lutetium-PSMA and docetaxel suggests a potential overall survival advantage for the sequence starting with chemotherapy. While PFS was similar, patients who received docetaxel first and then crossed over to lutetium at progression appeared to fare better, likely because they were guaranteed two life-prolonging therapies.